Small Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| # | Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|---|
| 1 |
1
Amarin
AMRN
$478M
| $478M | $11.31 | 0.62% |
|
| 2 |
2
Protalix BioTherapeutics
PLX
$257M
| $257M | $3.03 | 0.66% |
|
Small Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 2 small cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap between $250M and $2B — worth a combined $736M.
The largest by market cap are Amarin (AMRN) at $478M and Protalix BioTherapeutics (PLX) at $257M.
Among institutional investors, Protalix BioTherapeutics (PLX) drew the most net new fund positions in Q3 2026: 18 funds opened new positions, taking total fund holders up 3 (2.9%) quarter-over-quarter.
- Combined market cap: $736M across 2 stocks.
- Small Cap: market cap between $250M and $2B.
- Largest constituent: Amarin (AMRN), $478M market cap.
- Most net new fund positions in Q3 2026: Protalix BioTherapeutics (PLX), +3 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q3 2026.